Historical Valuation
Sensus Healthcare Inc (SRTS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.87 is considered Undervalued compared with the five-year average of 9.36. The fair price of Sensus Healthcare Inc (SRTS) is between 8.12 to 12.31 according to relative valuation methord. Compared to the current price of 4.76 USD , Sensus Healthcare Inc is Undervalued By 41.4%.
Relative Value
Fair Zone
8.12-12.31
Current Price：4.76
41.4%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Sensus Healthcare Inc (SRTS) has a current Price-to-Book (P/B) ratio of 1.32. Compared to its 3-year average P/B ratio of 1.50 , the current P/B ratio is approximately -12.13% higher. Relative to its 5-year average P/B ratio of 2.42, the current P/B ratio is about -45.50% higher. Sensus Healthcare Inc (SRTS) has a Forward Free Cash Flow (FCF) yield of approximately 3.22%. Compared to its 3-year average FCF yield of -7.01%, the current FCF yield is approximately -145.93% lower. Relative to its 5-year average FCF yield of -4.13% , the current FCF yield is about -177.85% lower.
P/B
Median3y
1.50
Median5y
2.42
FCF Yield
Median3y
-7.01
Median5y
-4.13
Competitors Valuation Multiple
AI Analysis for SRTS
The average P/S ratio for SRTS competitors is 8.53, providing a benchmark for relative valuation. Sensus Healthcare Inc Corp (SRTS.O) exhibits a P/S ratio of 1.87, which is -78.12% above the industry average. Given its robust revenue growth of -22.12%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for SRTS
1Y
3Y
5Y
Market capitalization of SRTS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SRTS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is SRTS currently overvalued or undervalued?
Sensus Healthcare Inc (SRTS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.87 is considered Undervalued compared with the five-year average of 9.36. The fair price of Sensus Healthcare Inc (SRTS) is between 8.12 to 12.31 according to relative valuation methord. Compared to the current price of 4.76 USD , Sensus Healthcare Inc is Undervalued By 41.40% .
What is Sensus Healthcare Inc (SRTS) fair value?
SRTS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Sensus Healthcare Inc (SRTS) is between 8.12 to 12.31 according to relative valuation methord.
How does SRTS's valuation metrics compare to the industry average?
The average P/S ratio for SRTS's competitors is 8.53, providing a benchmark for relative valuation. Sensus Healthcare Inc Corp (SRTS) exhibits a P/S ratio of 1.87, which is -78.12% above the industry average. Given its robust revenue growth of -22.12%, this premium appears unsustainable.
What is the current P/B ratio for Sensus Healthcare Inc (SRTS) as of Jan 10 2026?
As of Jan 10 2026, Sensus Healthcare Inc (SRTS) has a P/B ratio of 1.32. This indicates that the market values SRTS at 1.32 times its book value.
What is the current FCF Yield for Sensus Healthcare Inc (SRTS) as of Jan 10 2026?
As of Jan 10 2026, Sensus Healthcare Inc (SRTS) has a FCF Yield of 3.22%. This means that for every dollar of Sensus Healthcare Inc’s market capitalization, the company generates 3.22 cents in free cash flow.
What is the current Forward P/E ratio for Sensus Healthcare Inc (SRTS) as of Jan 10 2026?
As of Jan 10 2026, Sensus Healthcare Inc (SRTS) has a Forward P/E ratio of -34.17. This means the market is willing to pay $-34.17 for every dollar of Sensus Healthcare Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Sensus Healthcare Inc (SRTS) as of Jan 10 2026?
As of Jan 10 2026, Sensus Healthcare Inc (SRTS) has a Forward P/S ratio of 1.87. This means the market is valuing SRTS at $1.87 for every dollar of expected revenue over the next 12 months.